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Abstract
Platelet-rich plasma (PRP) containing hepatocyte growth factor (HGF) and other growth factors are widely used in
orthopaedic/sports medicine to repair injured tendons. While PRP treatment is reported to decrease pain in patients with
tendon injury, the mechanism of this effect is not clear. Tendon pain is often associated with tendon inflammation, and HGF
is known to protect tissues from inflammatory damages. Therefore, we hypothesized that HGF in PRP causes the anti-
inflammatory effects. To test this hypothesis, we performed in vitro experiments on rabbit tendon cells and in vivo
experiments on a mouse Achilles tendon injury model. We found that addition of PRP or HGF decreased gene expression of
COX-1, COX-2, and mPGES-1, induced by the treatment of tendon cells in vitro with IL-1b. Further, the treatment of tendon
cell cultures with HGF antibodies reduced the suppressive effects of PRP or HGF on IL-1b-induced COX-1, COX-2, and
mPGES-1 gene expressions. Treatment with PRP or HGF almost completely blocked the cellular production of PGE2 and the
expression of COX proteins. Finally, injection of PRP or HGF into wounded mouse Achilles tendons in vivo decreased PGE2
production in the tendinous tissues. Injection of platelet-poor plasma (PPP) however, did not reduce PGE2 levels in the
wounded tendons, but the injection of HGF antibody inhibited the effects of PRP and HGF. Further, injection of PRP or HGF
also decreased COX-1 and COX-2 proteins. These results indicate that PRP exerts anti-inflammatory effects on injured
tendons through HGF. This study provides basic scientific evidence to support the use of PRP to treat injured tendons
because PRP can reduce inflammation and thereby reduce the associated pain caused by high levels of PGE2.
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Introduction
Tendon injuries are a common condition encountered in
orthopaedic surgery and sports medicine practice. In the past few
decades, incidences of tendon injuries have increased significantly
in both recreational and highly-competitive athletes. Injured
tendons tend to heal slowly, particularly when the tendon
experiences severe contusion or rupture, which leads to tendon
retraction. Furthermore, healing tendons eventually form colla-
gen-rich scar tissue, which impairs tendon function and makes the
tendon susceptible to re-injury because the scar tissue has inferior
mechanical properties compared to intact tendons [1].
When tissues such as tendons are injured, the first phase of the
healing process is inflammation. During this phase, inflammatory
agents such as interleukin-1b (IL-1b) are produced by macro-
phages and other inflammatory cells at the injured site.
Additionally, the expression of cyclooxygenase (COX), including
the two isoforms COX-1 and COX-2, is upregulated. This
upregulation of COX leads to high cellular production of
prostaglandin E2 (PGE2), which is also mediated by PGE2
synthase (PGES), including membrane-associated PGE synthase
(mPGES) [2]. PGE2 is present at high levels in injured tendons and
causes vasodilatation [3] and hyperalgesia [4]. It is the target of
non-steroid anti-inflammatory drugs (NSAIDs), which are used to
reduce pain associated with tissue inflammation. PGE2 can also
increase the amount of substance P (SP), a major neuro-
transmitter of pain sensations [5], which is released in sensory
nerves. Therefore, PGE2 is considered to be a marker of tendon
inflammation [6].
In recent years, platelet-rich plasma (PRP) has been widely
adopted in clinics to treat injured tendons [7], as well as many
other musculoskeletal tissue injuries [8]. PRP is prepared by simple
centrifugation of whole blood to concentrate platelets and
simultaneously remove red blood cells. The resultant supernatant
is the PRP that contains various growth factors, including platelet
derived growth factor (PDGF), transforming growth factor (TGF),
fibroblast growth factor (FGF), vascular endothelial growth factor
(VEGF), and hepatocyte growth factor (HGF) [9]. These growth
factors are involved in the healing of injured tendons [10–12] and
are able to regulate cellular processes such as chemotaxis,
angiogenesis, mitogenesis, differentiation, and metabolism [13].
The rationale behind PRP therapy is that additional platelets will
increase the amounts of multiple growth factors released to a
localized injury site, which, in turn, will augment the healing
process in injured tissues.
In orthopaedic surgery and sports medicine, PRP has been most
extensively used in the treatment of ligament and tendon injuries
[7]. Many studies have demonstrated favorable outcomes of PRP
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therapy, such as improved healing of anterior cruciate ligament
(ACL) repair in animal models [14–16]. PRP treatments have also
been reported to improve clinical outcomes in injured tendons,
resulting in reduced pain scores along with increased functional
scores in elbow tendinosis [17,18]. In particular, after 1 year of
elbow tendinosis treatment with PRP or corticosteroids, 73% of
the patients in the PRP treated group had improved pain scores
(measured by VAS – Visual Analog Scale and DASH – Disabilities
of the Arm, Shoulder and Hand) when compared to ,50% in the
corticosteroid group [19]. In the same patients, after two years
without additional intervention, the results remained the same
with PRP treated patients showing a declining trend in pain scores,
which were significantly lower than the scores before treatment
while in the corticosteroid treated group the values were only
marginally below baseline scores [20]. These studies suggest that in
addition to its stimulatory effects on repair of injured tissues, PRP
can reduce tendon inflammation, which is associated with pain. In
addition, it is known that HGF, a key growth factor in PRP, has an
anti-inflammatory effect on injured organs; for example, it
attenuates the renal inflammatory response [21] and protects
against lung and liver injuries induced by inflammation [22,23].
Therefore, in this study we hypothesized that PRP exerts anti-
inflammatory effects on injured tendons through HGF. To test this
hypothesis, we performed cell culture experiments as an in vitro
model and a PRP or HGF injection experiment on injured mouse
Achilles tendons as an in vivo model. To assess whether platelet-
poor plasma (PPP) had similar effects to PRP, we further injected
PPP into mice. In both in vitro and in vivo model studies, the
expression of COX-1 and COX-2 genes and proteins, the
expression of mPGES-1 gene, and the production of PGE2, were
measured to evaluate cellular and tendon inflammation after
treatment with PRP or HGF. The results of this study indicate that
PRP has an anti-inflammatory effect, which is mediated by HGF
present in PRP preparations.
Materials and Methods
Ethics Statement
The University of Pittsburgh IACUC approved all protocols for
the use of rabbits for the in vitro model studies and mice for the
in vivo model studies. All surgeries were performed under general
anesthesia and efforts were made to minimize suffering to animals.
Tendon Cell Culture
Tendon cells derived from rabbit patellar tendons of 12 New
Zealand white rabbits (4–6 months old females) were used for cell
culture experiments. The procedures used to isolate tendon cells
were similar to those described previously [24], except that whole
tendon cell populations, collectively referred to as tendon cells,
were collected and cultured. Briefly, the patellar tendon sheath
was removed to obtain the core portion of the tendon. Tendon
samples were minced into small pieces and each 100 mg wet tissue
sample was digested in 1 ml PBS containing 3 mg collagenase type
I and 4 mg dispase at 37uC for 1 hr. After removing the enzymes
by centrifugation at 3,500 rpm for 15 min, the cells were cultured
in Dulbecco’s modified Eagle’s medium (DMEM; Lonza, Walk-
ersville, MD) supplemented with 20% fetal bovine serum (FBS;
Atlanta Biologicals, Lawrenceville, GA), 100 mM 2-mercaptoeth-
anol (Sigma-Aldrich, St. Louise, MO), 100 U/ml penicillin, and
100 mg/ml streptomycin (Atlanta Biologicals, Lawrenceville, GA).
The above procedures created a mixed cell population consisting
of tendon stem cells (TSCs) and tenocytes, which we defined as
tendon cells. In all culture experiments, tendon cells at passage 1
or 2 were used.
Preparation of PRP and PPP
PRP was prepared from autologous blood of the same animals,
which were used for tendon cell culture in vitro (rabbit PRP) or
in vivo (mouse PRP), based on our previously published protocol
[25]. This protocol produces PRP with a platelet concentration
that is about four times higher than in whole rabbit/mouse blood.
Briefly, for in vitro experiments, whole rabbit blood (9 ml) was
mixed with 1 ml 3.8% sodium citrate (SC) and 10 ml of the blood-
SC mixture was centrifuged at 500 g for 30 min. The supernatant
containing the concentrated platelets was then collected and
counted using Cell-DYN Emerald (Abbott Diagnostics; Lake
Forest). To activate platelets, the supernatant was treated with
22 mM CaCl2 at 37uC for 1 hr. The resulting supernatant,
referred to as PRP, was used immediately or stored at 4uC until
used for cell culture experiments.
For the in vivo experiments, PRP was obtained as described
above from 0.3 ml fresh blood collected from each mouse (n
= 60). The resultant PRP was immediately centrifuged at
10,000 rpm for 30 min at 4uC and the supernatant, referred to
as PPP, was transferred to a new tube. After counting the number
of platelets contained in the PRP and PPP with Cell-DYN
Emerald (Abbott Diagnostics; Lake Forest), both preparations
were mixed with 22 mM CaCl2, which eventually formed gels and
stored at 4uC until used for in vivo injection experiments.
Determination of HGF in Rabbit Whole Blood and PRP
Rabbit whole blood (4.5 ml) was withdrawn from an ear vein of
each rabbit and mixed with 0.5 ml 3.8% sodium citrate (SC); 1 ml
of blood-SC mixture was used as a whole blood sample, while rest
of the 4 ml blood-SC mixture were used for PRP preparations,
according to the above protocol. The concentrations of HGF in
whole blood and PRP preparations were measured using an
ELISA kit (TSZ ELISA, Cat. #RB1842, Framingham, MA). In
total, 7 rabbits were used to obtain HGF measurements.
In vitro Experiments
Tendon cells isolated from rabbit patellar tendons at passage 2
were seeded in 6-well plates at a density of 66104/well and
cultured in growth medium (20% FBS-DMEM) for 3 days, at
which point cells had reached about 90% confluence. The growth
medium was then replaced by serum-free medium (SF; Cat. #
S2640; Sigma, St. Louis, MO), and the cells were subjected to the
following treatments for 4 hrs. Group #1: SF only; group #2:
SF+IL-1b; group#3: SF+PRP+IL-1b; group#4: SF+PRP+IL-
1b+HGF antibody (AB); group #5: SF+PRP; group #6:
SF+PRP+HGF antibody (AB). A second set of six groups where
PRP was replaced with HGF was also maintained. Unless
otherwise noted, the following amounts of each component was
added to the cultures: 1 ng/ml IL-1b (Cat. # SRP3083; Sigma,
St. Louis, MO), a potent inflammatory cytokine, was used to
induce cellular inflammation according to a previous study [26];
10% (v/v) PRP was used to test its effect on tendon cell
inflammation; 1 ng/ml of HGF (human recombinant; Cat. #
294HG, R&D Systems, Minneapolis, MN) and 10 ng/ml of HGF
antibody (goat anti-human; Cat. # AB-294-NA, R&D systems,
Minneapolis, MN) were used wherever needed.
At the end of each treatment, cellular expressions of COX-1,
COX-2, and mPGES-1 genes were measured using quantitative
RT-PCR (qRT-PCR). In addition, the PGE2 production in
culture media was measured using an ELISA kit (Cayman
Chemical Co., Ann Arbor, MI). COX-1 and COX-2 protein
expression levels were also measured using Western blotting (see
below).
Anti-Inflammatory Function of PRP
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Gene Expression Analysis by qRT-PCR
After each treatment, RNA was extracted from cells in each
group using the RNeasy Mini Kit with an on-column DNase I
digest (Qiagen, Valencia, CA). First-strand cDNA was synthesized
from 1 mg total RNA in a 20 ml reaction by reverse transcription
using SuperScript II (Invitrogen, Grand Island, NY). The
following conditions for cDNA synthesis were applied: 65uC for
5 min and cooling at 4uC for 1 min, then 42uC for 50 min and
72uC for 15 min. Next, qRT-PCR was performed using
QuantiTect SYBR Green PCR Kit (QIAGEN, Valencia, CA).
In a 25 ml PCR reaction mixture, 2 ml cDNA (total 100 ng RNA)
were amplified in a Chromo 4 Detector (MJ Research, St. Bruno,
Quebec, Canada) by incubation at 94uC for 5 min, followed by 30
to 40 cycles of a three temperature program consisting of 1 min at
94uC, 40 seconds at 57uC, and 50 seconds at 72uC. The PCR
reaction was terminated after a 10 min extension at 70uC. Rabbit-
specific primers for COX-1, COX-2, mPGES-1, and glyceralde-
hyde 3-phosphate dehydrogenase (GAPDH), which was used as an
internal control, were adopted from previous studies (Table 1)
[27,28] and synthesized by Invitrogen. A no template control
(NTC) without cDNA was included for each primer pair and each
reaction had at least three replications. All parameters including
PCR efficiency, primer calibration and product specificity were
verified using standard qRT-PCR protocols. Relative expression
levels of each gene was calculated from the formula 22DDCT,
where DDCT= (CTtarget – CTGAPDH)treated – (CTtarget –
CTGAPDH)control. CT represents the cycle threshold of each cDNA
sample.
Western Blotting to Measure COX-1 and COX-2
Expression
At the end of each treatment, protein was first extracted from
cells in each group using the M-PER mammalian protein
extraction reagent (Thermo Scientific; Cat. #78505; Rockford,
IL), and then separated on 12% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) gel. The proteins
were then transferred onto Nitrocellulose membrane (Invitrogen;
Cat. #LC-2000; Carlsbad, CA) using a semi-dry blotting
apparatus (Bio-Rad; Hercules, CA) for 60 min at 2.0 mA/cm2.
COX-1 and COX-2 proteins were then detected using the
following antibodies: goat anti-COX-1 polyclonal antibody (1:500
room temperature for 3 hrs; Thermo Scientific; Cat. #PA1-
85118; Rockford, IL) and goat anti-COX-2 polyclonal antibody
(1:500 at room temperature for 3 hrs; Abcam; Cat. # ab35995;
Cambridge; MA) respectively. Mouse anti-GAPDH antibody was
used as a loading control (1:500 at room temperature for 3 hrs;
Abcam; Cat. #ab9484; Cambridge; MA) to detect GAPDH.
Then, peroxidase-conjugated mouse anti-goat IgG antibody
(1:1000 at room temperature for 2 hrs; Santa Cruz; Cat: #sc-
2354; Dallas, TX 75220) was used as the secondary antibody to
detect COX-1 and COX-2, and goat anti-mouse IgG-HRP
antibody (1:1000 at room temperature for 2 hrs; Santa Cruz; Cat:
#sc-2055; Dallas, TX 75220) was used for GAPDH. Finally, the
ECL Western Blotting Analysis System (GE Healthcare, Cat.
#RPN 2108, Buckinghamshire, HP, UK) was used to detect the
protein bands, which were visualized after exposure to X-ray films.
Immunostaining to Detect COX-1 and COX-2 Expression
Tendon cells at passage 2 were seeded in 12-well plates at a
density of 36104/well and treated with IL-1b, PRP, HGF, and/or
HGF antibody for 4 hrs before determining COX-1 and COX-2
expressions. After each treatment, COX-1 expression was tested
using goat anti-COX-1 (1:300) polyclonal antibody (Thermo
Scientific; Cat. #PA1-85118; Rockford, IL) and goat anti-COX-2
(1:300) polyclonal antibody (Abcam; Cat. # ab35995; Cambridge;
MA) at room temperature for 2 hrs followed by Cy3-conjugated
donkey anti-goat IgG (1:500) at room temperature for 1 hr as
secondary antibody to detect both COX-1, and COX-2 expres-
sion. The stained cells were examined using fluorescence
microscopy.
In vivo Injection Experiments
For in vivo injection experiments, mice instead of rabbits were
used. PRP and PPP from mice were prepared as described under
‘Preparation of PRP and PPP’. Under anesthesia, a wound with a
1 mm diameter was created on the Achilles tendon of each mouse
using a biopsy punch (Miltex, Inc., York, PA). The wounded mice
were divided into seven groups and the following injections were
given to the mice immediately after wounding: 20 mice were given
a 10 ml saline injection in each wound (wound only group); 20
mice were injected with 10 ml PRP in each wound (PRP group); 20
mice were injected with 10 ml PPP (PPP group); 20 mice were
given an injection of 3 ng HGF in 10 ml of an engineered tendon
matrix (ETM) prepared from rabbit patellar tendon according to
the published protocol [29] in each wound (HGF group); 20 mice
were given an injection of 3 ng HGF and 10 ng HGF antibody
(AB) in 10 ml of ETM (HGF+AB group); 20 mice were injected
with 10 ml ETM (ETM), and 20 mice were injected with 10 ml
PRP and 10 ng HGF antibody (AB) in 10 ml saline into each
wound (PRP+AB group). In these experiments PRP and PPP were
injected directly because both form gels in the wound area.
However, since HGF and anti-HGF antibody remain as liquids,
when injected individually or together, they were mixed with a
carrier such as ETM that forms a matrix after injection thereby
limiting the molecules to the wound area. After treatment, all mice
were allowed free cage activities. Four mice in each group were
sacrificed on days 0, 1, 3, 5, and 12 post-treatment, and the
Achilles tendons (two from the hind limbs of each mouse) were
harvested. Day 0 tendons were removed from mice immediately
after injections. PGE2 levels in tendon tissues were measured using
an ELISA kit (Cat. # 514010, Cayman Chemical Co, Ann Arbor,
MI), and COX-1 and COX-2 expressions were measured by
immunostaining of frozen tissue sections. For immunostaining, the
Table 1. Genes and primer sequences used in qRT-PCR.
Genes Primer sequences (Forward/Reverse) References
COX-1 59-TAGTGGACGCCTTCTCTCGC-39 59-CCGCTGCCATCTCTGTCTCT-39 [27]
COX-2 59-GGTGGAGATGATCTACCCGC-39 59-GGTTGAAAAGCAGCTCTGGG-39 [27]
mPGES-1 59-GCAGCGCACTGCTGGTTCTGAAGA-39 59-AGACCAGGCCCAGGAAGAGGAAA-39 [28]
GAPDH 59-AGGGTCATCATCTCAGCCCC-39 59-ATGCCTGCTTCACCACCTTC-39 [27]
doi:10.1371/journal.pone.0067303.t001
Anti-Inflammatory Function of PRP
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tissue samples were immersed into frozen section medium (Neg 50;
Richard-Allan Scientific; Kalamazoo, MI) in pre-labeled base
molds and were quickly frozen by placing in 2-methylbutane
chilled with liquid nitrogen. The frozen tissue blocks were then
placed on dry ice and subsequently stored in a deep freezer
(280uC) until they were used for histological and immunohisto-
chemical analyses.
COX-1 and COX-2 Expression in Tissue Sections
Determined by Immunohistochemistry
Each tissue was cut into 8 mm thick sections and fixed in 4%
paraformaldehyde for 15 min. The fixed sections were stained
with goat anti-COX-1 (1:300) polyclonal antibody (Thermo
Scientific; Cat. #PA1-85118; Rockford, IL) at room temperature
for 2 hrs, goat anti-COX-2 (1:300) polyclonal antibody (Abcam;
Cat. # ab35995; Cambridge; MA) at room temperature for 2 hrs
for primary binding, and FITC-conjugated rabbit anti-goat IgG
for COX-1 (1:500) at room temperature for 1 hr, or Cy-3
conjugated donkey anti-goat IgG antibody for COX-2 (1:500) at
room temperature for 1 hr for secondary binding and detection.
Stained cells were examined using fluorescence microscopy.
Measurement of PGE2 in Tendon Tissues
The procedure for PGE2 measurement is as follows: Mouse
Achilles tendon samples were weighed, minced, placed in buffer
(100 ml buffer for each 1 mg tissue) provided by the ELISA kit
manufacturer (Cayman Chemical Co., Ann Arbor, MI), and
homogenized. The tissue samples were centrifuged at 3,000 g for
30 min at 4uC, and the supernatant was collected to measure
PGE2 using an ELISA kit according to manufacturers’ instruc-
tions. The measured values were normalized with respect to tissue
weight.
Data Analysis
For each experimental condition, at least three replicates were
used. The findings presented in the results are representative of
these three replicates. All gene expression data gathered from
in vitro experiments were normalized to the serum-free group (SF),
which was the control. A two-tailed student t-test was used for
statistical analysis. A P-value less than 0.05 was considered to
indicate a statistically-significant difference between two groups.
Results
The Concentration of HGF in Whole Blood and PRP
PRP preparations used in tendon cell culture experiments
contained on an average, more than 3.5 times the level of HGF in
rabbit whole blood (Figure 1).
The Effects of PRP and HGF Treatments in vitro
COX-1 and COX-2 mRNA expression. Tendon cell
cultures were treated with 1 ng/ml of IL-1b to induce cellular
inflammation. After the addition of IL-1b, COX-1 gene expres-
sion in tendon cells was highly elevated (I) compared to non-
treated cells (SF) (Figure 2A). However, once 10% PRP was
added with IL-1b (P+I), COX-1 expression was almost completely
suppressed. Addition of HGF antibody to the PRP/IL-1b mix
(P+AB+I) abolished the suppressive effects of PRP and recovered
about 90% of COX-1 levels when compared to induction with IL-
1b alone. This indicates an interaction between PRP and HGF
antibody, and their influence on COX-1 expression. Additionally,
neither PRP alone (P) nor PRP plus HGF antibody (P+AB)
affected COX-1 expression (Figure 2A).
In a parallel culture experiment, the addition of HGF to tendon
cell culture that had been treated with IL-1b (H+I) resulted in
suppressive effects similar to those produced by PRP (Figure 2B);
that is, the application of HGF (1 ng/ml) nearly blocked IL-1b
induced COX-1 expression in tendon cells. The addition of HGF
antibody (10 ng/ml) along with HGF (1 ng/ml) greatly reduced
HGF’s suppressive effects on IL-1b induced COX-1 expression
(H+AB+I). However, such a combined use of HGF antibody with
HGF only partially (,70%) restored the COX-1 expression levels
induced by IL-1b treatment, suggesting that a higher dose of HGF
antibody may be needed to completely block the suppressive
effects of HGF on COX-1 expression.
The level of COX-2 expression in tendon cell culture was
similar to COX-1. Specifically, the same amount of IL-1b (1 ng/
ml) treatment caused a drastic increase in COX-2 gene expression
(I), but addition of 10% PRP to cell cultures almost abolished
COX-2 expression (P+I). The addition of HGF antibody (10 ng/
ml) with PRP (P+AB+I) nearly restored the level of COX-2
expression to control levels induced by IL-1b treatment
(Figure 3A). Likewise, treatment of tendon cell cultures with
both HGF and HGF antibody (H+AB+I) yielded results similar to
those produced by treatment with PRP and HGF antibody
(Figure 3B), indicating an interaction between PRP and HGF on
the IL-1b induced expression levels of COX-2.
mPGES-1 gene expression. In addition, PRP treatment
suppressed mPGES-1 expression induced by IL-1b treatment in
tendon cell cultures (P+I), whereas the addition of HGF antibody
reduced the suppressive effects of PRP (P+AB+I) (Figure 4A).
HGF treatment produced results similar to PRP treatment,
although HGF antibody together with HGF ‘‘restored’’ higher
percentage of mPGES-1 expression than with PRP (,50%
restoration with PRP vs. .90% with HGF) (Figure 4B).
PGE2 production. PRP treatment nearly blocked the cellular
production of PGE2 that was elevated by IL-1b treatment of
tendon cell cultures (Figure 5A). HGF treatment produced results
similar to those with PRP treatment (Figure 5B). The addition of
HGF antibodies to PRP or HGF in cell cultures partially (,60–
80%) restored PGE2 production levels compared to IL-1b treated
tendon cells.
COX-1 and COX-2 protein expression in vitro by western
blot. The addition of IL-1b to tendon cell cultures increased
both COX-1 and COX-2 protein expression levels (lane 2),
compared to the levels in the control group (lane 1). PRP
treatment decreased the effect of IL-1b on COX-1 and COX-2
expressions in an apparent dose-dependent manner (lanes 3, 4).
Moreover, PRP’s suppressive effect was nullified by the addition of
Figure 1. HGF levels in rabbit whole blood and PRP prepara-
tions. The concentration of HGF in PRP was over 3.5 times the
concentration found in rabbit whole blood (WB). The data are
expressed as mean 6 SD, n = 7.
doi:10.1371/journal.pone.0067303.g001
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HGF antibody (lanes 5, 6) (Figure 6A). HGF treatment also
inhibited the effects of IL-1b on COX-1 and COX-2 expressions
and HGF antibody decreased these inhibitory effects (Figure 6B).
The effects of PRP and HGF on COX-1 and COX-2 protein
levels by immunostaining. Immunostaining showed that
when compared to the control (Figure 7A) nearly all tendon
cells treated with IL-1b were positively stained for COX-1
(Figure 7B). The cellular inflammatory response, which is the
effect of IL-1b on COX-1 protein expression in this study, was
inhibited ,50% by 2% PRP (Figure 7C), but was completely
inhibited by 10% PRP (Figure 7D) and HGF (1 ng/ml)
(Figure 7E). On the other hand, the addition of 10 ng/ml of
HGF antibody to tendon cell cultures blocked such suppressive
effects of HGF and PRP completely (Figure 7F, G, H). Tendon
cells treated only with 2% PRP (Figure 7I), 10% PRP
(Figure 7J), HGF (1 ng/ml) (Figure 7K), or HGF+HGF
antibody (AB, 10 ng/ml) (Figure 7L) without IL-1b did not show
alterations in the levels of COX-1 but remained similar to the
control (Figure 7A).
Similarly, COX-2 expression induced by IL-1b (Figure 8B)
was more than 25% inhibited by 2% PRP (Figure 8C), 50%
inhibited by 10% PRP (Figure 8D), and more than 60% by 1 ng/
ml HGF (Figure 8E). The HGF antibody completely abolished
the suppressive effects of PRP and HGF on COX-2 (Figure 8F,
G, H). Similar to COX-1, the expression of COX-2 remained
unchanged when treated only with 2% PRP (Figure 8I), 10%
PRP (Figure 8J), HGF (1 ng/ml) (Figure 8K), or HGF+HGF
antibody (AB, 10 ng/ml) (Figure 8L) without IL-1b.
The Effects of PRP and PPP Treatments in vivo
The number of platelets in PRP used for in vivo injections was
about four times higher than the number of platelets in mouse
whole blood and about 60 times higher than the number of
platelets in PPP, which was used for a control group (Figure 9).
PGE2 production in vivo. PRP injections did not signifi-
cantly reduce PGE2 levels immediately after injection on day 0,
Figure 2. The effect of PRP (A) and HGF (B) treatment on COX-1
expression in tendon cell culture. Tendon cells were treated with
IL-1b, which resulted in high levels of COX-1 expression; however, the
addition of PRP (A) or HGF (B) together with IL-1b to the cell culture
markedly reduced the level of COX-1 expression. Also, PRP or HGF alone
did not alter COX-1 expression. Note that *P,0.05 is with respect to IL-
1b treatment (I); and #P,0.05 is with respect to the PRP+IL-1b (P+I)
group in A and the HGF+IL-1b (H+I) group in B. The data are expressed
as mean 6 SD, n = 4. SF: serum free medium; I: IL-1b; P+I: PRP+IL-1b;
P+AB+I: PRP+HGF antibody+IL-1b; P: PRP; P+AB: PRP+HGF antibody;
H+I: HGF+ IL-1b; H+AB+I: HGF+HGF antibody+IL-1b, H: HGF; and
H+AB: HGF+HGF antibody. Concentrations of the reagents used were:
IL-1b, 1 ng/ml; PRP, 10% (v/v); HGF, 1 ng/ml; HGF antibody, 10 ng/ml.
For SD values that are barely visible, the variation in gene expression
values was less than 5 (control group, SF is 1).
doi:10.1371/journal.pone.0067303.g002
Figure 3. The effects of PRP (A) and HGF (B) treatment on COX-
2 gene expression in tendon cell culture. Both PRP and HGF
treatments nearly abolished COX-2 expression, which was induced by
IL-1b treatment of tendon cells. Note that *P,0.05 is with respect to IL-
1b treatment condition (I); and #P,0.05 is with respect to the PRP+IL-
1b (P+I) group in A and the HGF+IL-1b (H+I) group in B. The data are
expressed as mean6 SD, n = 4. Label abbreviations and concentrations
of all agents (IL-1b, PRP, HGF, and HGF antibody) are identical to
legends in Figure 2. For SD values that are barely visible, the variation
in gene expression values was less than 5 (control group, SF is 1).
doi:10.1371/journal.pone.0067303.g003
Anti-Inflammatory Function of PRP
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but they significantly decreased PGE2 levels in wounded mouse
Achilles tendons on days 1, 3, and 5 post-treatment. On day 12,
PGE2 levels in both PRP injected and un-injected groups were
lower than on day 0 with no apparent effect of the PRP treatment
remaining (Figure 10A). On the other hand, PPP injections did
not significantly reduce the levels of PGE2 in mouse Achilles
tendons at any of the above time points (P.0.05). However, as
revealed by a trend analysis, PPP slightly reduced PGE2
production in the mouse tendons on days 1, 3, and 5
(Figure 10A). This is more likely due to the low abundance of
platelets in PPP (Figure 9). Furthermore, HGF injections reduced
PGE2 levels similar to PRP injections. Specifically, HGF
significantly decreased PGE2 levels on days 1, 3 and 12, albeit
to varying degrees (Figure 10B). On day 5, a slight reduction in
PGE2 levels was observed which was not statistically significant.
Note that on day 0 the treatment groups exhibited a transient
response to HGF treatment, as they had lower PGE2 levels than
the control group. This was likely due to the lag time (,1 hr) from
injection of HGF to harvesting and processing of mouse tendinous
tissues for PGE2 measurement. Further, the injection of HGF
antibody into wounded mouse Achilles tendons, completely
inhibited the HGF effect and PGE2 production was similar to
the control (wounded only group) (Figure 10B). Addition of HGF
antibody into wounded Achilles, also blocked the suppressive effect
exerted by PRP, and PGE2 production was much higher than the
group injected with PRP only (Figure 10C). In these experiments,
the results from saline injections (wound only group – red columns)
were similar to those from ETM injections; therefore, the results
from the saline injected group only are presented here as the
control.
COX-1 and COX-2 protein expression in vivo. Stained
tissue sections showed that both COX-1 and COX-2 expression
were markedly increased in wounded Achilles tendons day 3 after
wounding (Figure 11A, B). However, 3 days after the injection of
10 ml PRP into wounded tendons, COX-1 and COX-2 expression
levels were markedly decreased (Figure 11C, D). Further,
injection of 3 ng HGF in 10 ml saline into wounded mouse
Achilles tendons (Figure 12A, B) also decreased COX-1 and
COX-2 expression on day 3 post-treatment (Figure 12C, D).
Figure 4. The effects of PRP (A) and HGF (B) treatment on
mPGES-1 gene expression in tendon cell culture. IL-1b treatment
increased mPGES-1 expression (I), but its effect was almost completely
suppressed by PRP (A) or HGF (B) treatment. Note that *P,0.05 is with
respect to IL-1b treatment condition (I); and #P,0.05 is with respect to
the PRP+IL-1b (P+I) group in A and the HGF+IL-1b (H+I) group in B. The
data are expressed as mean 6 SD, n = 4. Label abbreviations and
concentrations of all agents (IL-1b, PRP, HGF, and HGF antibody) are
identical to legends in Figure 2. For SD values that are barely visible,
the variation in gene expression values was less than 5 (control group,
SF is 1).
doi:10.1371/journal.pone.0067303.g004
Figure 5. The effects of PRP (A) and HGF (B) treatments on
PGE2 production in tendon cell culture. IL-1b treatment (I) induced
high levels of PGE2 production in cells compared to levels induced by
control conditions (SF); however, these increases in PGE2 were
markedly reduced by PRP or HGF treatment. Note that *P,0.05 is with
respect to IL-1b treatment condition (I); and #P,0.05 is with respect to
the PRP+IL-1b (P+I) group in A and the HGF+IL-1b (H+I) group in B. The
data are expressed as mean 6 SD, n = 4. Label abbreviations and
concentrations of all agents (IL-1b, PRP, HGF, and HGF antibody) are
identical to legends in Figure 2. For SD values that are barely visible,
the variation in gene expression values was less than 5 (control group,
SF is 1).
doi:10.1371/journal.pone.0067303.g005
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Discussion
Injured tendons are difficult to repair and are susceptible to re-
injury, as healing typically results in the formation of mechani-
cally-inferior scar tissue. In fact, the restoration of normal structure
and function to injured tendons is one of the most challenging
tasks in orthopaedic surgery and sports medicine [30]. Currently,
autologous PRP has been adopted as a promising treatment option
for tendon injury. However, the efficacy of PRP treatment is
highly controversial [8,31,32]. We suggest that this confusion
partially stems from the fact that the mechanism of PRP’s effects
on the inflammatory response of injured tendons is poorly defined.
This study was designed to determine the potential effects of PRP
treatment on tendon inflammation following injury in an animal
model. Using both in vitro and in vivo models, this study demon-
strated that PRP and HGF treatments suppressed the IL-1b-
induced gene expression of COX-1, COX-2, and mPGES-1, the
protein expression of COX-1 and COX-2, and the production of
PGE2 in tendon cell culture. Finally, the use of HGF antibody with
PRP or HGF could block PRP/HGF’s suppressive effects on
tendon cell inflammation. Taken together, the findings of this
study indicate that PRP exerts an anti-inflammatory effect on
injured tendons, which is mediated, at least in part, by HGF.
As a mediator of PRP’s anti-inflammatory action, as shown in
this study, HGF is a pleiotropic factor and plays an essential role in
the regulation of cell proliferation, survival, and differentiation in
various organs [33]. Our finding that rabbit PRP contained high
levels of HGF is consistent with the established facts on PRP. HGF
is not only contained within PRP, but is also produced by human
tendon cells [34] and human bone marrow stem cells in culture
[35]. Therefore, it is likely that HGF was also produced in our
tendon cell cultures, and newly produced HGF could add to the
blocking effects of exogenously added HGF.
Moreover, HGF is known to function both as an anti-
inflammation agent and as a remarkable anti-fibrotic regulator
[36]. Its anti-inflammatory action is primarily mediated by the
disruption of transcription factor NF-kB signaling, which is a
critical regulator of inflammation. This was demonstrated both
in vivo and in vitro in renal inflammation of mouse [33] and human
chondrocytes in vitro [37]. This mechanism of HGF action was
presumably responsible for the anti-inflammatory effects of HGF
on COX-1, COX-2, and PGE2 production observed in this study.
In this regard, the anti-inflammatory effects of PRP and HGF
have mechanisms similar to those of NSAIDs, which inhibit COX
expression and, as a result, PGE2 production in injured tissues. We
suggest that the findings of this study may explain how PRP
treatment of tendon injuries in human subjects effectively
improves pain and function in a clinical setting: PRP likely
reduced tendon inflammation and, consequently, alleviated pain,
which resulted in improved functional scores in tendon injury
patients [17,18].
It is well established that COX, especially COX-2, is a major
marker of tissue inflammation [38,39]. COX converts arachidonic
acid (AA) into prostaglandins, which are further converted into
PGE2 by PGE2 synthase (PGES), including mPGES. PGE2
induces vasodilation, vascular permeability, and nociception, and
is a major mediator of acute inflammation and pain in tendons
and other tissues [2,40,41]. Furthermore, high levels of PGE2 not
only result in exacerbated inflammation, but also suppress matrix
synthesis [42]. For example, treatment of human tenocytes with
PGE2 in culture decreases cell proliferation and collagen
production [43], induces aberrant differentiation of TSCs into
non-tenocytes in vitro [44] and induces degenerative changes in
rabbit tendons [45]. Thus, the suppressive effects of PRP on COX
expression and PGE2 production shown in this study will provide
multiple benefits: PRP can not only reduce tendon inflammation
and associated pain in clinics, but can also promote the repair of
injured tendons. In addition, growth factors contained in PRP can
produce stimulatory effects on tendon healing and the fibrin gel in
PRP could serve as a natural scaffold to attract cells and, as a
result, accelerate tendon healing.
It is known that PRP may contain variable levels of IL-1
receptor antagonist (IL-1ra), as shown in human serum [46]. IL-
1ra may block the induction of cellular inflammation in culture by
exogenous IL-1b. Additionally, HGF could upregulate IL-1ra
expression, thus exerting its anti-inflammatory effects on the
tendon cells [20]. However, this potential effect of serum IL-1ra on
tendon cell inflammation in our culture experiments must be
much smaller than the effects of HGF, because the combined use
of PRP and HGF antibody restored more than 60–70% of COX-1
and COX-2 expressions (Figures 2A, 3A) and PGE2 production
(Figure 5A), which was induced by IL-1b treatment of tendon cell
culture, to levels comparable with PRP treatment alone. There-
fore, we suspect that in normal serum derived from healthy
animals (rabbits and mice in this study), IL-1ra levels are either
low, or may be degraded during the process of PRP preparation,
or a combination of the two.
An interesting finding in our in vivo model is that while PPP
injection did not significantly reduce PGE2 levels, it apparently
caused a small reduction of PGE2 production in wounded mouse
Achilles tendons on days 0, 1, 3, and 5 post-treatment
(Figure 10A). This effect is similar to PRP, although much
smaller, probably due to the much lower number of platelets in
Figure 6. The effects of PRP (A) and HGF (B) treatment on COX-
1 and COX-2 protein expression in tendon cell culture. Total
proteins extracted from tendon cells after treatments were separated
on 12% SDS-PAGE and transferred onto nitrocellulose membrane to
detect COX-1 and COX-2 proteins using goat anti-COX-1 and goat anti-
COX-2 polyclonal antibodies, respectively, and peroxidase-conjugated
rabbit anti-goat IgG antibody as secondary antibody. A. PRP treatment.
Lane 1: serum free medium (SF); lane 2: IL-1b (1 ng/ml); lane 3: PRP
(2%)+IL-1b (1 ng/ml); lane 4: PRP (10%)+ IL-1b (1 ng/ml); lane 5: PRP
(2%)+ IL-1b (1 ng/ml)+HGF antibody (10 ng/ml); lane 6: PRP (10%)+IL-
1b (1 ng/ml)+HGF antibody (10 ng/ml). Notice that 10% PRP reduced
COX-1 expression, but almost completely inhibited COX-2 expression
(lane 4 vs. lane 2). B. HGF treatment. Lane 1: SF; lane 2: IL-1b (1 ng/ml);
lane 3: HGF (1 ng/ml)+IL-1b (1 ng/ml); lane 4: HGF (1 ng/ml); and lane 5:
HGF (1 ng/ml)+IL-1b (1 ng/ml)+HGF antibody (10 ng/ml). Also notice
that HGF at 1 ng/ml markedly reduced both COX-1 and COX-2
expression (lane 3 vs. lane 2).
doi:10.1371/journal.pone.0067303.g006
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PPP than in PRP (Figure 9). In addition, PPP could possibly
contain certain serum factors exerting an inhibitory effect on
PGE2 production in the wounded tendons. This finding suggests
that PRP’s effects on the inflammation of injured tendons are
platelet concentration-dependent, and that blood clots, which
contain fewer concentrated platelets than PRP, but a higher
number of platelets than PPP, can exert anti-inflammatory effects
at injured tissue sites. While HGF in mouse PRP was not
measured, previous studies have shown that mouse serum contains
HGF [47,48], a finding consistent with our in vitro experiments.
HGF in mouse PRP and PPP may mediate the anti-inflammatory
effects observed in our in vivo experiments.
Now a further explanation of the cell culture model used in this
study may be necessary to enable a better understanding of our
experimental results. First, when tendons are injured, inflamma-
tion ensues, which is characterized by an initial upregulation of IL-
1b production in injured sites [49]. IL-1b, which is secreted mainly
by macrophages, is a potent inflammatory cytokine that
upregulates the expression of other inflammatory mediators,
including COX and matrix metallopeptidase. Second, tendon
cells are known to respond to IL-1b treatment by upregulating
COX expression and increasing production of PGE2 [6,26,50].
Therefore, the use of IL-1b and tendon cells may serve as an
appropriate in vitro model to simulate tendon inflammation in vivo.
However, a limitation of the current in vitro model is that
mechanical loading was not incorporated. Because patients
resume daily activities after PRP injection, mechanical loading
placed on injured tendons should be an important factor in
assessing the efficacy of PRP treatment on injured tendons. In
clinics, training regiments are often prescribed, which may have
additive effects on tendon inflammation. Based on this, we suggest
that appropriate exercise after PRP treatment is likely beneficial,
as small mechanical loading on tenocytes suppresses cellular
inflammation [26]; however, intensive exercise should be avoided
because large mechanical loading may further worsen cellular
inflammation by increasing the production of PGE2 [44].
In our in vivo mouse model, while injections of PRP significantly
reduced the production of PGE2, they did not completely suppress
PGE2 levels. This may be attributed to a few factors. The first is
the PRP composition. In the PRP preparations, we did not
separate white blood cells (WBCs) from platelets because of the
small volume of mouse blood. Therefore, our PRP preparations
Figure 7. The effects of PRP or HGF treatment on COX-1 protein expression in tendon cell culture by immunostaining. Tendon cells in
culture were treated with IL-1b, PRP, HGF, and/or HGF antibody (AB) to determine COX-1 expression using goat anti-COX-1 antibody and Cy-3
conjugated donkey anti-goat IgG antibody. Red represents COX-1 protein; and blue represents nuclei stained with Hoechst 33342. IL-1b treatment
induced a high level of COX-1 expression in tendon cells compared to the control conditions (A); however, such an increase in COX-1 was markedly
reduced by PRP or HGF treatments. The addition of HGF antibody to tendon cell cultures decreased the reduction by PRP or HGF treatments. A: SF
(control conditions); B: IL-1b (1 ng/ml); C: 2%PRP+ IL-1b; D: 10%PRP+IL-1b; E: HGF+IL-1b; F: 2%PRP+IL-1b+AB; G: 10%PRP+IL-1b+AB; H: HGF+IL-
1b+AB; I: 2%PRP; J: 10%PRP; K: HGF (1 ng/ml) and L: HGF+AB (10 ng/ml). Bar: 100 mm.
doi:10.1371/journal.pone.0067303.g007
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likely contained inflammatory agents (e.g. IL-1b and TNF-a)
released from WBCs, which may cause exacerbated inflammation.
The second reason may be the PRP concentration used in the
animal experiment. Only one dosage of PRP (, 4 times the
platelet number of mouse whole blood) was used for injection. It is
possible that the use of higher doses of PRP and, as a result, higher
levels of HGF, would further reduce tendon inflammation marked
by high levels of PGE2. However, the complete suppression of
PGE2 production is not desirable, since under normal conditions,
tendons contain a basal level of PGE2 [44]. This PGE2 may play
an important role in tendon remodeling [51].
In our in vivo study, we used acutely injured tendons of young
mice as an experimental model to investigate the anti-inflamma-
tory effects of PRP. The disadvantage with this model is that it
does not replicate the chronic tendon inflammation and/or
degeneration typical in chronic tendon injury or tendinopathy
[52]. Future research should evaluate the effects of PRP treatment
on tendinopathy in an animal model. However, it should be noted
that the anti-inflammatory effects produced by PRP injection and
mediated by HGF, as shown in this study, should be independent
of acute or chronic tendon injuries.
Figure 8. The effects of PRP or HGF treatment on COX-2 protein expression in tendon cell culture by immunostaining. Tendon cells in
culture were treated with IL-1b, PRP, HGF, and/or HGF antibody (AB) to determine COX-2 expression using goat anti-COX-2 antibody and Cy-3
conjugated donkey anti-goat IgG antibody. Red represents COX-2 protein; and blue represents nuclei stained with Hoechst 33342. Similar to COX-1
results (Figure 7), PRP or HGF treatments markedly reduced COX-2 expression, and the combined use of HGF antibody with PRP or HGF decreased
the reduction effects produced by either PRP or HGF treatment alone. Label abbreviations (A to L) are the same as in Figure 7. Bar: 100 mm.
doi:10.1371/journal.pone.0067303.g008
Figure 9. Platelet numbers in mouse whole blood, PRP, and
PPP preparations used for the in vivo experiments. On average,
the number of platelets in PRP preparations was about four times
higher than in mouse whole blood (WB), whereas the number was 60
times higher in PRP than in PPP preparations (*P,0.05 is with respect to
WB). The data are expressed as mean 6 SD, and n =8.
doi:10.1371/journal.pone.0067303.g009
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It should be stressed that this study was intended to determine
whether PRP’s use to treat tendon inflammation had a sound
‘‘theoretical basis’’ (specifically, this study hoped to identify PRP’s
specific anti-inflammatory mechanism), which turned out to be the
case as revealed both by our in vitro and in vivo data. However,
whether PRP therapy will be an effective treatment for any
particular tendon injury in a clinical setting can be complicated by
a number of patient factors, including age, treatment history,
disease history, etc. All these factors, which are not accounted for
in the in vitro and in vivo models of this study, are expected to create
huge variations in PRP treatment outcomes [53]. This is
particularly true for the general patient population, as opposed
to the most active and highly-competitive athletic population. The
former is expected to be more variable because of its diverse
patient populations, while the later may constitute a more
homogenous population.
Figure 10. The effects of PRP, PPP, HGF and HGF antibody on PGE2 production in wounded mouse Achilles tendons in vivo. A. PRP
and PPP injections. Injections with PRP significantly reduced PGE2 levels in tendons on days 1, 3, and 5 post-treatment. However, on day 12, PRP’s
effect on PGE2 production in tendon tissues was little, if any. On day 0, little difference was observed in PGE2 levels between PRP-treated and non-
treated tendons. However, PPP treatment did not significantly decrease PGE2 levels in the tendon tissues at all time points post-treatment (P.0.05).
However, a small suppression effect on days 1, 3, and 5 likely occurred, as PPP-treated tendons had consistently lower PGE2 levels than control
tendons injected with saline. B. HGF injection. Injection with HGF decreased PGE2 production in wounded Achilles tendons, producing results similar
to PRP injections except on day 12, when HGF injection still significantly decreased PGE2 production (*P,0.01 is with respect to control tendons
given saline injections). Addition of HGF+HGF antibody (AB) largely negated the suppressive effect of HGF. C. PGE2 production in mouse tendons
injected with PRP and HGF antibody. Injection of PRP along with HGF antibody into wounded Achilles tendons restored PGE2 levels to normal on all
days 1, 3, 5 and 12. The data in Figure 10A, B, C are expressed as mean 6 SD, and n = 4 (4 mice).
doi:10.1371/journal.pone.0067303.g010
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Clinically, NSAIDs are frequently used in the treatment of
tendinopathies to reduce tendon inflammation and associated
pain; however, these drugs have serious side effects, ranging from
mild symptoms, such as dyspepsia and abdominal discomfort, to
more serious adverse events, such as peptic ulcers and life-
threatening gastric/duodenal bleeding and perforation [54]. As a
result of these side effects, the clinical use of NSAIDs is severely
limited. Moreover, while NSAIDs may provide some pain relief to
patients, they do not improve the healing process of injured tissues
[55] and have been shown to abolish exercise-induced adaptive
increases in collagen synthesis in human tendons [56,57]. On the
other hand, PRP is thought to be inherently safe because of its
autologous nature. Therefore, the anti-inflammatory function of
PRP shown in this study makes PRP an attractive alternative
option for treating tendon inflammation and associated pain in
clinics.
Conclusions
This study demonstrates that PRP treatment suppresses tendon
cell inflammation in vitro and tendon inflammation in vivo, marked
by the upregulation of COX-1, COX-2, and mPGES-1 expres-
sions, as well as high levels of PGE2 production. This anti-
inflammatory function of PRP is at least partially mediated
through HGF, a major growth factor in PRP, which produces
anti-inflammation results similar to PRP. These findings indicate
that PRP exerts anti-inflammatory effects on injured tendons,
which may explain why PRP treatments in clinics can improve
tendon function in patients with tendon injury. Future research is
required to determine optimal PRP dosage regimens, to evaluate
the different effects produced by varied PRP compositions, and to
evaluate the interactive effects between PRP treatment and
exercise regimens (or mechanical loading) on injured tendons.
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